EFFICACY OF LOW OR STANDARD DOSE RITUXIMAB AS COMPARED TO PONTICELLI'S REGIMEN IN MEMBRANOUS NEPHROPATHY

被引：0
|
作者：
Roccatello, Dario [1 ,2 ]
Fenoglio, Roberta [1 ,2 ]
Sciascia, Savino [1 ,2 ]
机构：
[1] S Giovanni Bosco Hosp, Turin, Italy
[2] Univ Turin, Turin, Italy
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2019年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
FP239
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
    Yao-Wei Wang
    Xin-Hui Wang
    Hong-Xia Wang
    Ren-Huan Yu
    World Journal of Clinical Cases, 2023, (03) : 566 - 575
  • [42] Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up
    Zonozi, Reza
    Laliberte, Karen
    Huizenga, Noah R.
    Rosenthal, Jillian K.
    Jeyabalan, Anushya
    Collins, A. Bernard
    Cortazar, Frank B.
    Niles, John L.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 78 (06) : 793 - 803
  • [43] Successful treatment of patients with refractory idiopathic membranous nephropathy with low-dose Rituximab: A single-center experience
    Wang, Yao-Wei
    Wang, Xin-Hui
    Wang, Hong-Xia
    Yu, Ren-Huan
    WORLD JOURNAL OF CLINICAL CASES, 2023, 11 (03) : 566 - 575
  • [44] Intravenous cyclophosphamide as an alternative to the oral cyclophosphamide modified Ponticelli regimen for high-risk PLA2R-positive membranous nephropathy
    Stefan, Gabriel
    Zugravu, Adrian
    Stancu, Simona
    JOURNAL OF NEPHROLOGY, 2023, 36 (02) : 293 - 295
  • [45] Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study
    Zhang, Shasha
    Huang, Jing
    Dong, Jianwei
    Li, Zhuo
    Sun, Mengyao
    Sun, Yujiao
    Chen, Bing
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [46] Evaluating the Efficacy of Rituximab in Primary Membranous Nephropathy: An Observational Study from Southern India
    Saigal, Megha
    Guditi, Swarnalatha
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 514 - 514
  • [47] Intravenous cyclophosphamide as an alternative to the oral cyclophosphamide modified Ponticelli regimen for high-risk PLA2R-positive membranous nephropathy
    Gabriel Ștefan
    Adrian Zugravu
    Simona Stancu
    Journal of Nephrology, 2023, 36 : 293 - 295
  • [48] Efficacy analysis of rituximab in treating patients with primary membranous nephropathy dependent on calcineurin inhibitors
    Li, Zhuo
    Zhao, Tingting
    Zhang, Shasha
    Huang, Jing
    Wang, Honggang
    Sun, Yujiao
    Wang, Rong
    Chen, Bing
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [49] Efficacy and safety of rituximab in the treatment of membranous nephropathy A systematic review and meta-analysis
    Lu, WanJun
    Gong, ShuHao
    Li, Juan
    Luo, HongWen
    Wang, Ying
    MEDICINE, 2020, 99 (16) : E19804
  • [50] Cost Effectiviness of Rituximab Given At Fixed Dose (1000 mg on days 1 and 15) Compared to the Standard Regimen in adult's Immune Thrombocytopenia.
    Mahevas, Matthieu
    Ebbo, Mikael
    Audia, Sylvain
    Bonnotte, Bernard
    Schleinitz, Nicolas
    Haioun, Corinne
    Khellaf, Medhi
    Godeau, Bertrand
    Michel, Marc
    BLOOD, 2012, 120 (21)
12345